Department of Cardiology, Biomedical Research (Therapy) Center, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Med Sci Monit. 2012 Jul;18(7):HY27-31. doi: 10.12659/msm.883193.
Endothelial progenitor cells (EPCs) play a protective role in the cardiovascular system by enhancing the maintenance of endothelium homeostasis and the process of new vessel formation. Recent studies show that EPCs may induce vascular regeneration and neovascularization mainly through paracrine signaling, that is, through the secretion of growth factors and pro-angiogenic cytokines. However, multiple factors might function synergistically and therefore make it difficult to manipulate EPC paracrine effects. MicroRNAs, a family of small, non-coding RNAs, are characterized by post-transcriptionally regulating multiple functionally related genes, which renders them potentially powerful therapeutic targets or tools. In this paper we propose the hypothesis that microRNAs can be utilized as a novel therapeutic strategy for regulating EPC paracrine secretion.
内皮祖细胞 (EPCs) 通过增强内皮稳态的维持和新血管形成的过程，在心血管系统中发挥保护作用。最近的研究表明，EPCs 可能主要通过旁分泌信号转导诱导血管再生和新血管形成，即通过生长因子和促血管生成细胞因子的分泌。然而，多种因素可能协同作用，因此难以操纵 EPC 的旁分泌效应。微小 RNA（miRNA）是一类小的非编码 RNA，其特征是通过转录后调节多个功能相关的基因，使其成为潜在的强大治疗靶点或工具。在本文中，我们提出了一个假说，即微小 RNA 可以作为一种调节 EPC 旁分泌分泌的新型治疗策略。
